BCL11B predetermines a persister state in breast cancer that is reversed by TNFα
Qi, Z.;Gulati, G.;Kuo, A.;Sikandar, S.;Ho, W.;Qian, D.;Dirbas, F.;Newman, A.;Cai, S.;Clarke, M.
Show abstract
The frequent development of chemoresistance in cancer presents a significant clinical challenge, yet the underlying causes for heterogeneous drug responses remain largely elusive. Here, we systematically assessed the cellular differentiation status of human breast cancer cells utilizing single-cell atlases and identified a distinct population of immature basal-like cancer cells marked by BCL11B. Notably, higher levels of BCL11B+ cancer cells are significantly associated with early relapse in breast cancer patients who received chemotherapy. Functioning as a central regulator, BCL11B delineates an immature cell state that preferentially transitions to a drug-resistant persister state during treatment through multiple pre-existing and adaptive drug-resistance programs. Importantly, the cytokine tumor necrosis factor alpha (TNF) is revealed as a natural inhibitor of BCL11B and can directly reverse the emergence of chemoresistant persister cells. Therefore, we identify BCL11B as an unappreciated pre-determinant of drug response and a therapeutic target for a subset of breast cancer patients at high risk of developing chemoresistance.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer 96%
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 96%
- A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription 96%
Similar papers in this journal
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 96%
- Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. 96%
- Laterally transferred macrophage mitochondria acts as a signaling source promoting cancer cell proliferation 95%
Similar papers in this journal
Similar papers in this journal
- Neoplastic immune mimicry potentiates breast tumor progression 98%
- Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response 97%
- Targeting the dependence on PIK3C3-mTORC1 signaling in dormancy-prone breast cancer cells blunts metastasis initiation 97%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.